JP6501913B2 - 慢性創傷治療用の組成物、その製造方法及びそれを用いた慢性創傷治療用のドレッシング材 - Google Patents
慢性創傷治療用の組成物、その製造方法及びそれを用いた慢性創傷治療用のドレッシング材 Download PDFInfo
- Publication number
- JP6501913B2 JP6501913B2 JP2017556937A JP2017556937A JP6501913B2 JP 6501913 B2 JP6501913 B2 JP 6501913B2 JP 2017556937 A JP2017556937 A JP 2017556937A JP 2017556937 A JP2017556937 A JP 2017556937A JP 6501913 B2 JP6501913 B2 JP 6501913B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- acid
- chronic wounds
- treating chronic
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010052428 Wound Diseases 0.000 title claims description 66
- 208000027418 Wounds and injury Diseases 0.000 title claims description 66
- 230000001684 chronic effect Effects 0.000 title claims description 50
- 239000000203 mixture Substances 0.000 title claims description 35
- 238000004519 manufacturing process Methods 0.000 title claims description 12
- 239000000463 material Substances 0.000 title claims description 7
- 239000003102 growth factor Substances 0.000 claims description 75
- 239000011159 matrix material Substances 0.000 claims description 46
- 229920006317 cationic polymer Polymers 0.000 claims description 25
- 229920006318 anionic polymer Polymers 0.000 claims description 23
- 239000003431 cross linking reagent Substances 0.000 claims description 23
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 20
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 20
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 20
- 239000011259 mixed solution Substances 0.000 claims description 15
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 14
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 14
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 12
- 102000008186 Collagen Human genes 0.000 claims description 12
- 108010035532 Collagen Proteins 0.000 claims description 12
- 229920001436 collagen Polymers 0.000 claims description 12
- 229920002674 hyaluronan Polymers 0.000 claims description 12
- 229960003160 hyaluronic acid Drugs 0.000 claims description 12
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 235000010418 carrageenan Nutrition 0.000 claims description 8
- 229920001525 carrageenan Polymers 0.000 claims description 8
- 238000004132 cross linking Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- -1 salt compounds Chemical class 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 6
- 229920002873 Polyethylenimine Polymers 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 239000000679 carrageenan Substances 0.000 claims description 6
- 229940113118 carrageenan Drugs 0.000 claims description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229920000333 poly(propyleneimine) Polymers 0.000 claims description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
- 102000009123 Fibrin Human genes 0.000 claims description 4
- 108010073385 Fibrin Proteins 0.000 claims description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 229920000209 Hexadimethrine bromide Polymers 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 108010039918 Polylysine Proteins 0.000 claims description 4
- 102000007327 Protamines Human genes 0.000 claims description 4
- 108010007568 Protamines Proteins 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 4
- 229960000633 dextran sulfate Drugs 0.000 claims description 4
- 229950003499 fibrin Drugs 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 229920000058 polyacrylate Polymers 0.000 claims description 4
- 239000004584 polyacrylic acid Substances 0.000 claims description 4
- 229920000656 polylysine Polymers 0.000 claims description 4
- 229940048914 protamine Drugs 0.000 claims description 4
- HPILSDOMLLYBQF-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COC(CCC)OCC1CO1 HPILSDOMLLYBQF-UHFFFAOYSA-N 0.000 claims description 3
- 239000004971 Cross linker Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 239000000908 ammonium hydroxide Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920000962 poly(amidoamine) Polymers 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000004952 Polyamide Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000012929 tonicity agent Substances 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 8
- 101800003838 Epidermal growth factor Proteins 0.000 description 8
- 229940116977 epidermal growth factor Drugs 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical group O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- UWFRVQVNYNPBEF-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(C)C=C1C UWFRVQVNYNPBEF-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDPLHDGYGLENEI-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)propan-2-yloxymethyl]oxirane Chemical compound C1OC1COC(C)COCC1CO1 HDPLHDGYGLENEI-UHFFFAOYSA-N 0.000 description 1
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150061656A KR101777910B1 (ko) | 2015-04-30 | 2015-04-30 | 만성창상 치료용 조성물, 이의 제조방법 및 이를 이용한 만성창상 치료용 드레싱재 |
| KR10-2015-0061656 | 2015-04-30 | ||
| PCT/KR2015/004473 WO2016175358A1 (ko) | 2015-04-30 | 2015-05-04 | 만성창상 치료용 조성물, 이의 제조방법 및 이를 이용한 만성창상 치료용 드레싱재 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018515478A JP2018515478A (ja) | 2018-06-14 |
| JP6501913B2 true JP6501913B2 (ja) | 2019-04-17 |
Family
ID=57199196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556937A Active JP6501913B2 (ja) | 2015-04-30 | 2015-05-04 | 慢性創傷治療用の組成物、その製造方法及びそれを用いた慢性創傷治療用のドレッシング材 |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP6501913B2 (zh) |
| KR (1) | KR101777910B1 (zh) |
| CN (1) | CN107708722A (zh) |
| WO (1) | WO2016175358A1 (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108066805B (zh) * | 2016-11-17 | 2021-06-01 | 大连敏慧精益科技有限公司 | 一种ε-聚赖氨酸仿生抑菌膜及其制备和应用 |
| KR20180076063A (ko) * | 2016-12-27 | 2018-07-05 | (주) 삼보 | 덱스트란 기반의 창상피복재 및 그 제조방법 |
| KR102218427B1 (ko) * | 2017-09-20 | 2021-02-22 | 차의과학대학교 산학협력단 | 단백질 약물을 포함하는 코아세르베이트 조성물 및 이를 포함하는 창상 치료제 |
| KR102350526B1 (ko) * | 2018-08-16 | 2022-01-17 | (주)메디제이 | 응집성이 개선된 창상피복재 조성물의 제조 방법 |
| CN113226232A (zh) * | 2018-10-24 | 2021-08-06 | 索尼奥环球控股有限责任公司 | 功能性伤口愈合敷料 |
| CN113174092B (zh) * | 2021-05-17 | 2022-10-25 | 西安交通大学 | 透明质酸-ε-聚赖氨酸盐酸盐的聚离子复合物、制备方法及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034375A (en) * | 1988-08-10 | 1991-07-23 | Institute Of Molecular Biology, Inc. | Process of wound healing using PDGF and EGF |
| KR100366439B1 (ko) | 2000-02-21 | 2003-01-09 | 주식회사 대웅 | 상피세포 성장인자를 유효성분으로 하는 안정한 약제학적조성물 |
| US7494669B2 (en) * | 2001-02-28 | 2009-02-24 | Carrington Laboratories, Inc. | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
| JP2004161684A (ja) * | 2002-11-13 | 2004-06-10 | Nitto Denko Corp | 生理活性物質含有創傷治癒用フィルム製剤 |
| JP2005152298A (ja) * | 2003-11-26 | 2005-06-16 | Techno Surg:Kk | マトリックスとその製造方法 |
| KR20080104932A (ko) * | 2007-05-29 | 2008-12-03 | 금오공과대학교 산학협력단 | 키토산, 생분해성 고분자 및 세포성장인자를 함유하는나노섬유 부직포 |
| CN102120033A (zh) * | 2011-03-07 | 2011-07-13 | 温州医学院 | 促口腔额面部多种创伤修复的复合生长因子的胶原蛋白缓释载体材料及其制备方法 |
| JP5780818B2 (ja) * | 2011-04-21 | 2015-09-16 | オリンパス株式会社 | 駆動装置およびそれを用いた画像装置 |
| JP5935181B2 (ja) * | 2012-04-24 | 2016-06-15 | カオシュン メディカル ユニヴァーシティ | 創傷治癒用の生体材料およびその調製 |
-
2015
- 2015-04-30 KR KR1020150061656A patent/KR101777910B1/ko active IP Right Grant
- 2015-05-04 JP JP2017556937A patent/JP6501913B2/ja active Active
- 2015-05-04 WO PCT/KR2015/004473 patent/WO2016175358A1/ko active Application Filing
- 2015-05-04 CN CN201580081275.5A patent/CN107708722A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016175358A1 (ko) | 2016-11-03 |
| JP2018515478A (ja) | 2018-06-14 |
| KR101777910B1 (ko) | 2017-09-13 |
| CN107708722A (zh) | 2018-02-16 |
| KR20160129459A (ko) | 2016-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6501913B2 (ja) | 慢性創傷治療用の組成物、その製造方法及びそれを用いた慢性創傷治療用のドレッシング材 | |
| Yuan et al. | A physicochemical double cross-linked multifunctional hydrogel for dynamic burn wound healing: shape adaptability, injectable self-healing property and enhanced adhesion | |
| Feng et al. | Chitosan-based functional materials for skin wound repair: Mechanisms and applications | |
| Gao et al. | In situ formation of injectable hydrogels for chronic wound healing | |
| EP2773696B1 (en) | Self-assembled composite ultrasmall peptide-polymer hydrogels | |
| JP2021007754A (ja) | インサイチュー架橋性ポリマー組成物およびその方法 | |
| Zhuo et al. | Injectable hyaluronan-methylcellulose composite hydrogel crosslinked by polyethylene glycol for central nervous system tissue engineering | |
| JP2018511622A (ja) | 擬塑性ミクロゲルマトリクスの組成物およびキット | |
| US20120039959A1 (en) | Anti-Adhesion Alginate Barrier of Variable Absorbance | |
| US10369106B2 (en) | Efficient aqueous encapsulation and controlled release of bioactive agents | |
| CA2416698A1 (en) | Hydrogel films and methods of making and using therefor | |
| JP2007521937A (ja) | タンパク質ポリマーおよび多機能スペーサーを含む創傷被覆材 | |
| CN111494709B (zh) | 兼具抗肿瘤和抑菌功能的促组织修复水凝胶的制备及应用 | |
| Zhang et al. | The dual delivery of growth factors and antimicrobial peptide by PLGA/GO composite biofilms to promote skin-wound healing | |
| AU2017378904A1 (en) | Injectable hydrogels and applications thereof | |
| KR20160038120A (ko) | 알지네이트 하이드로젤 및 이의 제조방법 | |
| CN101912633A (zh) | 一种透明质酸海绵及其制备方法 | |
| WO2016149615A1 (en) | Polypeptide compositions and methods of using the same | |
| CN107224605B (zh) | 一种高透气性烧烫伤敷料的制备方法 | |
| JP2005046228A (ja) | マット及びそれを用いた医療品 | |
| CN114288463B (zh) | 一种流体胶原蛋白止血材料的研制方法 | |
| Davenport et al. | Engineered biomaterials for chronic wound healing | |
| Tachaboonyakiat | Physical and Chemical Modification of Chitin/Chitosan for Functional Wound Dressings | |
| Magagula et al. | GG Lenetha Department of Life Sciences, Central University of Technology, Private Bag X1, Bloemfontein, South Africa | |
| US20200222577A1 (en) | Biomaterials comprising gelatin derived from cold-adapted aquatic species |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181023 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190121 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190226 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190319 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6501913 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |